首页 » 文章 » 文章详细信息
Cancer Medicine Volume 7 ,Issue 11 ,2018-10-10
Postoperative chemotherapy had no prognostic effect on early‐staged young ovarian cancer with unilateral resection
Clinical Cancer Research
Xiaofei Zhang 1 , 2 Shuoer Wang 2 , 3 SongJiao Zhao 4 Yidi Sun 5 Gong Yang 1 , 2 , 3
Show affiliations
DOI:10.1002/cam4.1822
Received 2018-08-30, accepted for publication 2018-09-12, Published 2018-09-12
PDF
摘要

Abstract Postoperative chemotherapy has been widely used in the treatment of early‐staged ovarian cancer patients underwent unilateral resection, but the clinical decision mainly depends on the doctor’s experience without a well‐defined guideline. This study used propensity score matching to analyze the effect of postoperative chemotherapy for early‐staged ovarian cancer patients underwent unilateral resection on prognosis. Patients of age 50 or younger than 50 with early‐staged ovarian cancer were explored from the Surveillance, Epidemiology, and End Results program database during 2000‐2018. Propensity score matching was used to randomize the dataset and reduce the selection biases. Univariate and multivariate cox proportional hazards models were utilized to estimate the necessity of chemotherapy. In univariate analysis of matched population, both the overall survival and cancer‐specific survival analysis showed that chemotherapy had no effect on the prognosis of early‐staged young ovarian cancer patients (Overall survival, P = 0.477; Cancer‐specific survival, P = 0.950). In propensity‐adjusted multivariate analysis, chemotherapy still had no effect on both the overall and cancer‐specific survival probability after excluding the effect of all the confounding factors (HR = 0.863, CI = 0.587‐1.269, P = 0.455; HR = 1.009, CI = 0.633‐1.607, P = 0.970). Our study suggested that postoperative chemotherapy is not necessary for early‐staged young ovarian cancer patients with unilateral resection, as indicated by both the overall survival and cancer‐specific survival.

关键词

propensity score matching;premenopausal women;ovarian cancer;chemotherapy

授权许可

© 2018 Published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

图表

Chemotherapy demonstrated no significant benefit to patients with early‐staged ovarian cancer who underwent unilateral resection for both overall survival and cancer‐specific survival. Overall survival probability (A) or cancer‐specific survival probability (B) of patients with early‐staged ovarian cancer who underwent unilateral resection underwent or without chemotherapy

Table 1

Table 2

Table 3

Table 4

Table 5

通讯作者

Gong Yang.Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China;Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China;Central Laboratory, The Fifth People's Hospital of Shanghai Fudan University, Shanghai, China.yanggong@fudan.edu.cn

推荐引用方式

Xiaofei Zhang,Shuoer Wang,SongJiao Zhao,Yidi Sun,Gong Yang. Postoperative chemotherapy had no prognostic effect on early‐staged young ovarian cancer with unilateral resection. Cancer Medicine ,Vol.7, Issue 11(2018)

您觉得这篇文章对您有帮助吗?
分享和收藏
0

是否收藏?

参考文献
[1] Boussios S, Moschetta M, Tatsi K, Tsiouris AK, Pavlidis N. A review on pregnancy complicated by ovarian epithelial and non‐epithelial malignant tumors: diagnostic and therapeutic perspectives. J Adv Res. 2018;12:1‐9.
[2] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7‐30.
[3] Hara T, Nishikawa K, Sakatoku M, Oba K, Sakamoto J, Omura K. Phase II study of weekly paclitaxel, cisplatin, and 5‐fluorouracil for advanced gastric cancer. Gastric Cancer. 2011;14(4):332‐338.
[4] Morgan RJ, Armstrong DK, Alvarez RD, et al. Ovarian cancer, version 1.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN. 2016;14(9):1134‐1163.
[5] Ozkok A, Edelstein CL. Pathophysiology of cisplatin‐induced acute kidney injury. BioMed Res Int. 2014;2014:967826.
[6] Gornstein E, Schwarz TL. The paradox of paclitaxel neurotoxicity: Mechanisms and unanswered questions. Neuropharmacology. 2014;76(Pt A):175‐183.
[7] Leslie KK, Koil C, Rayburn WF. Chemotherapeutic drugs in pregnancy. Obstet Gynecol Clin North Am. 2005;32(4):627‐640.
[8] Donati A, Castro LG. Cutaneous adverse reactions to chemotherapy with taxanes: the dermatologist's point of view. An Bras Dermatol. 2011;86(4):755‐758.
[9] Boehmerle W, Huehnchen P, Peruzzaro S, Balkaya M, Endres M. Electrophysiological, behavioral and histological characterization of paclitaxel, cisplatin, vincristine and bortezomib‐induced neuropathy in C57Bl/6 mice. Sci Rep. 2014;4:6370.
[10] Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 2014;25(18):2677‐2681.
[11] Serkies K, Wegrzynowicz E, Jassem J. Paclitaxel and cisplatin chemotherapy for ovarian cancer during pregnancy: case report and review of the literature. Arch Gynecol Obstet. 2011;283(Suppl 1):97‐100.
[12] Sedletska Y, Giraud‐panis MJ, Malinge JM. Cisplatin is a DNA‐damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr Med Chem Anticancer Agents. 2005;5(3):251‐265.
文献评价指标
浏览 39次
下载全文 5次
评分次数 0次
用户评分 0.0分
分享 0次